Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New York
Clinical trial register · United States · industry-sponsored

Clinical Trials in New York, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 45 Texas 33 Florida 32 New York 31 Massachusetts 25
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Genentech, Inc.2 Klus Pharma Inc.1 Jazz Pharmaceuticals1 Alyssum Therapeutics1 STORM Therapeutics LTD1
State
California45 Texas33 Florida32 New York31 Massachusetts25
All 43 states
Target enrolment
to

Trials with a site in New York

31 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
DrugPanitumumab
Astellas Pharma Inc
Phase 1
364
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Recruiting
STORM Therapeutics LTD
Phase 1/2
107
California, Florida, Massachusetts, Michigan, New York, Ohio, Texas, Virginia
2025-05-05
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
DrugZanzalintinib
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor
DrugAbemaciclib
Tango Therapeutics, Inc.
Phase 1/2
191
Arizona, California, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2025-03-24
Active, closed
GlaxoSmithKline
Phase 1/2
14
California, Colorado, Michigan, New York, Pennsylvania
2024-12-13
Recruiting
Genentech, Inc.
Phase 1
410
California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Michigan, New York
2024-11-14
Recruiting
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06401356Hematologic Malignancy, Solid Tumor, Advanced Malignancies
DrugPelabresib
Novartis Pharmaceuticals
Phase 3
50
California, Florida, Illinois, Michigan, New York
2024-08-13
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926Melanoma Stage IV, Solid Tumor
Georgiamune Inc
Phase 1/2
117
Arizona, California, Massachusetts, Montana, New York, Ohio, Tennessee, Virginia
2024-05-09
Recruiting
Biohaven Therapeutics Ltd.
Phase 1/2
500
California, District of Columbia, Florida, Georgia, Michigan, Missouri, New York, Oklahoma
2024-04-22
Active, closed
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
Affini-T Therapeutics, Inc.
Phase 1/2
100
California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin
2024-03-06
Recruiting
Alyssum Therapeutics
Phase 1/2
100
Arizona, California, New York, Oregon, Texas
2024-02-13
Recruiting
OnCusp Therapeutics, Inc.
Phase 1
263
Colorado, Connecticut, Florida, Massachusetts, Michigan, New York, Oklahoma, Tennessee
2024-02-09
Recruiting
BeOne Medicines
Phase 1
337
California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas
2023-09-21
Active, closed
A2 Biotherapeutics Inc.
Phase 1/2
160
Arizona, California, Florida, Minnesota, Missouri, New York, Texas
2023-04-28
Active, closed
DEKA Biosciences
Phase 1
39
California, New York, Oklahoma, Texas, Virginia
2023-04-03
Active, closed
Klus Pharma Inc.
Phase 2
240
Indiana, Kentucky, Maryland, Minnesota, New York, Texas, Virginia
2023-01-17
Recruiting
Sanofi
Phase 1/2
542
Delaware, Iowa, Kansas, Michigan, New Jersey, New York, Rhode Island, Texas
2022-11-29
Active, closed
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma
DrugTYRA-300
Tyra Biosciences, Inc
Phase 1/2
310
Massachusetts, New York, North Carolina, Ohio, Tennessee, Washington
2022-11-22
Active, closed
Jazz Pharmaceuticals
Phase 1
98
California, Colorado, Florida, Illinois, New York, Oklahoma, Pennsylvania, Tennessee
2022-10-10
Recruiting
Impact Therapeutics, Inc.
Phase 1/2
61
New Jersey, New York, South Carolina, Texas
2022-02-11
Active, closed
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
NCT05199272Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer
23andMe, Inc.
Phase 1/2
141
California, Georgia, Michigan, New York, Oregon, Tennessee, Texas, Virginia
2021-12-29
Recruiting
Simcha IL-18, Inc.
Phase 1/2
316
Arizona, Colorado, Connecticut, Florida, Massachusetts, New York
2021-08-06
Active, closed
Presage Biosciences
Early Phase 1
15
Louisiana, New York, North Carolina, Ohio, Oregon, Pennsylvania, South Carolina, Washington
2021-07-26
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
DrugGivastomig
I-Mab Biopharma US Limited
Phase 1
330
California, Colorado, Indiana, Massachusetts, New Jersey, New York, North Carolina, Tennessee
2021-06-29
Active, closed
IDEAYA Biosciences
Phase 1
169
Arizona, Arkansas, California, Florida, Indiana, Maryland, Massachusetts, New York
2021-04-14
Recruiting
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
NCT04516447Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
DrugsAzenosertib·Pegylated liposomal doxorubicin·Gemcitabine·Paclitaxel
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1
172
Colorado, Massachusetts, Missouri, New York, North Carolina, Rhode Island, Tennessee, Texas
2020-10-26
Active, closed
Daiichi Sankyo
Phase 1
40
New York, Ohio
2020-10-09
Recruiting
Oxford BioTherapeutics Ltd
Phase 1
200
Arizona, California, Florida, Iowa, Kentucky, Mississippi, New Mexico, New York
2019-07-25
Active, closed
Genentech, Inc.
Phase 1
200
Massachusetts, New York, Tennessee
2016-12-13
Active, closed
Eli Lilly and Company
Phase 1
223
Kentucky, New York, Texas
2016-11-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
370
Colorado, Illinois, Massachusetts, New York, North Dakota, South Dakota, Texas
2015-03-19
Rows per page Showing 1–31 of 31
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-usa/state/new-york

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 11 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 31 of those studies with a site in New York that also match the filters currently applied.

How many clinical trials are recruiting in New York?

18 of the 31 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (New York), 31 studies
PhaseStudiesRecruitingShare
Phase 114845.2%
Phase 1/214945.2%
Early Phase 1103.2%
Phase 2103.2%
Phase 3113.2%

Most active sponsors

Lead sponsors with the most studies (New York)
Lead sponsorStudiesRecruiting
Genentech, Inc.21
23andMe, Inc.10
A2 Biotherapeutics Inc.10
Affini-T Therapeutics, Inc.10
Alyssum Therapeutics11
Astellas Pharma Inc11
BeOne Medicines11
Biohaven Therapeutics Ltd.11
Daiichi Sankyo10
DEKA Biosciences10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.